We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+12.09%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$823M
AUM Growth
-$2.43M
Cap. Flow
-$27.4M
Cap. Flow %
-3.33%
Top 10 Hldgs %
55.08%
Holding
68
New
13
Increased
12
Reduced
21
Closed
14

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$14.4M
2
LJPC
La Jolla Pharmaceutical Company
LJPC
+$13.6M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$11.6M
4
CORI
Corium International, Inc.
CORI
+$9.81M
5
PETX
Aratana Therapeutics, Inc.
PETX
+$9.16M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$19.9M
2
ADXS
Advaxis Inc
ADXS
+$12.4M
3
MDCO
Medicines Co
MDCO
+$10.5M
4
DRRX
DURECT Corp
DRRX
+$8.93M
5
SPNE
SeaSpine Holdings Corporation Common Stock
SPNE
+$8.63M

Sector Composition

Rank Sector Weight
1 Healthcare 74.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVDQ
26
DELISTED
Novadaq Technologies Inc.
NVDQ
$11.7M 1.42%
+1,000,000
New +$7.91M
AMRN
27
Amarin Corp
AMRN
$285M
$10.2M 1.24%
126,682
-15,000
-11% -$933K
MRTX
28
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$9.09M 1.1%
2,490,801
+400,000
+19% +$1.53M
JUNO
29
DELISTED
Juno Therapeutics, Inc.
JUNO
$7.83M 0.95%
262,100
+86,400
+49% +$2.13M
NVET
30
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
$7.54M 0.92%
1,127,200
– –
PGNX
31
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$6.79M 0.82%
1,000,000
-998,531
-50% -$7.37M
PRTK
32
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$6.68M 0.81%
277,020
+53,158
+24% +$1.18M
ACGN
33
DELISTED
Aceragen Inc
ACGN
$6.63M 0.81%
28,359
– –
CDTX
34
DELISTED
Cidara Therapeutics
CDTX
$6.12M 0.74%
40,814
+12,670
+45% +$1.75M
LJPC
35
CALL
DELISTED
La Jolla Pharmaceutical Company
LJPC
$4.47M 0.54%
+150,000
New +$4.3M
NUVA
36
DELISTED
NuVasive, Inc.
NUVA
$4.3M 0.52%
+55,900
New +$4.18M
HRTX icon
37
CALL
Heron Therapeutics
HRTX
$86.9M
$4.17M 0.51%
+300,900
New +$4.36M
NTUS
38
DELISTED
Natus Medical Inc
NTUS
$4.16M 0.51%
+111,500
New +$4.03M
ZGNX
39
DELISTED
Zogenix, Inc.
ZGNX
$3.81M 0.46%
+262,500
New +$3.3M
ELGX
40
DELISTED
Endologix Inc
ELGX
$3.79M 0.46%
77,934
-88,968
-53% -$5.24M
ARLZ
41
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$2.75M 0.33%
2,034,103
-3,157,487
-61% -$4.56M
ADMA icon
42
ADMA Biologics
ADMA
$1.94B
$2.52M 0.31%
681,346
-347,326
-34% -$1.39M
CBIO
43
Crescent Biopharma
CBIO
$629M
$2.48M 0.3%
+2,218
New +$1.83M
IRTC icon
44
iRhythm Holdings
IRTC
$3.54B
$2.24M 0.27%
+52,700
New +$1.92M
GMED icon
45
Globus Medical
GMED
$10.2B
$2.21M 0.27%
+66,700
New +$2.09M
CFRX
46
DELISTED
ContraFect Corporation
CFRX
$1.92M 0.23%
1,657
-129
-7% -$151K
CGNT
47
DELISTED
Cogentix Medical, Inc.
CGNT
$1.91M 0.23%
1,094,544
+340,771
+45% +$584K
MDWD icon
48
MediWound
MDWD
$183M
$1.19M 0.14%
24,952
-65,491
-72% -$3.05M
ATEC icon
49
Alphatec Holdings
ATEC
$1.26B
$1.1M 0.13%
594,533
+368,527
+163% +$744K
TPST icon
50
Tempest Therapeutics
TPST
$15M
$429K 0.05%
+94
New +$398K
1
2
3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q2 2017 Portfolio in Review

As of Q2 2017, Broadfin Capital held 68 positions worth $823M, down 0.29% from $826M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Broadfin Capital withdrew a net $27.4M in Q2 2017, closing 14 positions and reducing 21 holdings. Its most notable exit was Advaxis Inc, an estimated $12.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 77% a quarter earlier.

Against the trend, Broadfin Capital opened a new position in Aerie Pharmaceuticals worth $16.3M.

  • Broadfin Capital's largest Q2 2017 buy was Aerie Pharmaceuticals: 310,000 shares worth $16.3M.
  • Broadfin Capital added most to La Jolla Pharmaceutical Company in Q2 2017, an estimated $13.6M increase.
  • Broadfin Capital's biggest Q2 2017 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $19.9M.
  • Broadfin Capital fully exited Advaxis Inc in Q2 2017, selling an estimated $12.4M.
  • Broadfin Capital's ten largest holdings make up 55% of its $823M portfolio in Q2 2017.
  • Broadfin Capital opened 13 new positions and closed 14 in Q2 2017.
  • Broadfin Capital's portfolio value fell 0.29% quarter-over-quarter to $823M.

Based on Broadfin Capital's 13F filing for Q2 2017, filed 14 Aug 2017.